Pharma CEOs

Novartis CEO Vas Narasimhan is raising the bar on second-gen cancer drug studies
Novartis CEO Vas Narasimhan is raising the bar on second-gen cancer drug studies
Endpoints
Novartis
cancer
Pharma CEOs
Vas Narasimhan
Flag link:
How big is too big for a CEO bonus target? Annoyed Shire investors have some ideas
How big is too big for a CEO bonus target? Annoyed Shire investors have some ideas
Fierce Pharma
Shire
Pharma CEOs
executive pay
investors
Flemming Ornskov
Flag link:
Novartis CEO: How To Create Cheaper Alternatives To The Most Expensive Drugs
Novartis CEO: How To Create Cheaper Alternatives To The Most Expensive Drugs
Forbes
Novartis
Pharma CEOs
FDA
drug pricing
Vasant Narasimham
Flag link:
Hopes rise for Shire sale as Takeda CEO discusses case for deal
Hopes rise for Shire sale as Takeda CEO discusses case for deal
NASDAQ.com
Shire
Takeda
Pharma CEOs
M&A
Christophe Weber
Flag link:
Which Big Pharma CEOs Least Deserved Their Big Pay Increases?
Which Big Pharma CEOs Least Deserved Their Big Pay Increases?
Motley Fool
Big Pharma
Pharma CEOs
executive pay
AbbVie
Bristol-Myers Squibb
Gilead Sciences
JNJ
Pfizer
Flag link:
After 2016's monster bonus—and investor complaints—Valeant CEO's pay crashes from $62M to $5M
After 2016's monster bonus—and investor complaints—Valeant CEO's pay crashes from $62M to $5M
Fierce Pharma
Valeant Pharmaceuticals
Pharma CEOs
Joseph Papa
executive pay
Flag link:
Teva joins the executive pay big leagues after doling out $17M to new CEO Kare Schultz
Teva joins the executive pay big leagues after doling out $17M to new CEO Kare Schultz
Fierce Pharma
Teva Pharmaceutical
executive pay
Kåre Schultz
Pharma CEOs
Flag link:
Bristol-Myers CEO Giovanni Caforio nets $18.7M in 2017 pay, a 10% raise
Bristol-Myers CEO Giovanni Caforio nets $18.7M in 2017 pay, a 10% raise
Fierce Pharma
Bristol-Myers Squibb
Pharma CEOs
Giovanni Caforio
executive pay
Flag link:
Revenue down? No worries for Gilead CEO Milligan as compensation swells to $15.4M
Revenue down? No worries for Gilead CEO Milligan as compensation swells to $15.4M
Endpoints
Gilead Sciences
Pharma CEOs
John Milligan
executive pay
Flag link:
Glaxo's Boss Looks Ready to Loosen the Straitjacket
Glaxo's Boss Looks Ready to Loosen the Straitjacket
Bloomberg
GSK
Emma Walmsley
Pharma CEOs
consumer health
Pfizer
M&A
Flag link:
Shire CEO sees Microsoft tie-up building momentum for faster rare disease diagnosis
Shire CEO sees Microsoft tie-up building momentum for faster rare disease diagnosis
Fierce Pharma
Shire
Pharma CEOs
Microsoft
rare disease
Flemming Ornskov
Flag link:
AbbVie chief racks up $22.6M in 2017 pay, complete with $600K in personal jet use
AbbVie chief racks up $22.6M in 2017 pay, complete with $600K in personal jet use
Fierce Pharma
AbbVie
Richard Gonzalez
Pharma CEOs
executive pay
Flag link:
Is Pfizer's CEO Ian Read Really Worth 61% More?
Is Pfizer's CEO Ian Read Really Worth 61% More?
Motley Fool
Pfizer
Ian Read
Pharma CEOs
executive pay
Flag link:
Pfizer Lifts CEO's Pay 61% to $27.9 Million With Retention Bonus
Pfizer Lifts CEO's Pay 61% to $27.9 Million With Retention Bonus
Bloomberg
Pfizer
Ian Read
executive pay
Pharma CEOs
Flag link:
GlaxoSmithKline chief Emma Walmsley nets $6.8M in pay in her first year at the helm
GlaxoSmithKline chief Emma Walmsley nets $6.8M in pay in her first year at the helm
Fierce Pharma
GSK
Emma Walmsley
Pharma CEOs
executive pay
Flag link:
Forget that 'no breakup' vow. Allergan's CEO now says a strategic review is happening
Forget that 'no breakup' vow. Allergan's CEO now says a strategic review is happening
Fierce Pharma
Allergan
Pharma CEOs
Brent Saunders
spinoffs
Flag link:
Lousy year for shareholders, but Allergan CEO Brent Saunders sprints past Gorsky, Gonzalez with $32M pay package
Lousy year for shareholders, but Allergan CEO Brent Saunders sprints past Gorsky, Gonzalez with $32M pay package
Endpoints
executive pay
Pharma CEOs
Allergan
Brent Saunders
Alex Gorsky
Richard Gonzalez
Flag link:
From drugmaker to drug manager: Ex-GSK chief Andrew Witty jumps to the helm of giant Optum
From drugmaker to drug manager: Ex-GSK chief Andrew Witty jumps to the helm of giant Optum
Endpoints
Andrew Witty
GSK
Pharma CEOs
OptumRx
PBMs
Flag link:
Reckitt CEO stands by Mead Johnson deal, despite Pfizer option
Reckitt CEO stands by Mead Johnson deal, despite Pfizer option
Yahoo/Reuters
Reckitt Benckiser
Pharma CEOs
Mead Johnson
Pfizer
M&A
consumer health
Flag link:
Merck C.E.O. Ken Frazier on Death Row Cases and the Corporate Soul
Merck C.E.O. Ken Frazier on Death Row Cases and the Corporate Soul
NY Times, NY
Merck
Pharma CEOs
Kenneth Frazier
Flag link:

Pages